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 CHIMAERAS AND ACTUALITY 
 
 
Laura VILCHES ARMESTO Researcher at the CRID laura.vilchesarmesto@fundp.ac.be 
Philippe LAURENT Researcher at the CRID philippe.laurent@fundp.ac.be 
Lawyer at the Brussels Bar (MVVP) 
 
Medical data is usually addressed by lawyers from a privacy point of view. However, 
intellectual property is increasingly put forward when discussing the control, the use or the 
transmission of medical data. Even if medical data relates to patients and is moreover 
protected by very strict data protection and secrecy rules, this information is nonetheless 
“created”, sorted, structured, explained and, more generally, processed by the professional 
practitioners and medical administrations. Given this processing of the data and the drafting 
of files and reports concerning the health condition of the patients, one could indeed 
assume that these intellectual investments should be worth some legal protection. One 
should however still bear in mind the particularities of the considered data and the strict 
conditions to be fulfilled in order to benefit from one or another intellectual property right. 
    
This paper may be seen as an introduction to the application of Intellectual Property to 
medical data, tackled on the basis of two examples. The first part will focus on the 
application of copyright rules to medical records of patients. The second part will address 
the protection of biobanks from a database and patent rights point of view. 
 
 
PART I. Copyright to medical records? 
 
I.1. Ideas and information are free 
 
Is there was to ever be a golden rule in copyright, then this would probably be the one. By 
utilizing this as a paradigm, several copyright principles emerge that will be summarized 
hereunder. 
 
Copyright is a free and automatic protection that is granted without any formality on 
literary and artistic works, which include amongst others, any production in the scientific 
domain.  Copyright is only granted to works that are expressed in a certain form1 and are 
original.  
 
The meeting of the first condition, namely the embodiment of the work in a form, is the 
starting of the protection by copyright: copyright is granted at the moment of the creation of 
the work. This condition specifies also the subject matter of copyright: copyright protection  
only extends to the form of the work, and not to the underlying ideas or information. As 
regards scientific articles, for instance, copyright will never protect the facts, figures, 
information, theories, discoveries or other scientific analysis that are used or described in 
the text: only the latter will be protected against the mere plagiarism of its structure and/or 
wording. In other words, copyright never allows an author to oppose the rewriting of the 




The second and last condition for a work to be copyrighted is originality. The definition of 
an original work differs slightly from one legal system to another. In civil law countries 
(such as Belgium or France) this means that the work should be marked by the personality 
of the author. In Anglo-Saxon countries, this will imply that the work must originate from 
the author who should have expended “skill, judgement and labour” on its creation. In both 
systems, this condition entails that the author should at least have a breathing space 
allowing him to choose the way he will express himself and give form to the work. When 
there are no alternative ways to write this information or data, this means that the 
expression of these information and data is not original and, therefore, not copyrighted. 
 
Medical codes of ethics or patient rights regulations usually provide for minimal content of 
patients’ records, such as identification data (name, contact details, birth date, sex, 
profession), date, diagnosis and prescribed treatment for each visit, date and results of 
medical exams, urgency data (allergies, pathologies, etc.) and, in general, any information 
that could prove to be useful in order to complete a diagnosis and carry on an efficient 
treatment.  At first sight, the above data could be considered as pure information falling 
outside copyright protection. A medical record that only consists of the gathering of this 
information, which would most often be the case, should therefore not be granted any 
copyright protection.  
 
However, one could imagine some particular situations where a practitioner has completed 
the record with some personal comments or analysis written in a more elaborated or literary 
form that could prove to be original, and therefore, capable of being copyrighted. One could 
also imagine that the way this information is presented on the paper record (colours, 
columns, tables, etc…) could be copyrighted. The “author”, namely the practitioner entitled 
with copyright, could therefore normally benefit from some exclusive rights on this “work”. 
He would have the exclusive right to authorise or forbid any reproduction of the record and 
its communication to the public by any mean (including diffusion on the internet), unless 
one of those acts is covered by an exception to copyright.  Furthermore, on the basis of his 
moral right, the practitioner would have the right to agree or not with the divulgation of the 
work, to claim for credits and to oppose  any modification.   
 
I.2. Copyrights against patients’ rights? 
 
A practitioner in a position to claim copyrights on a patient record should be entitled 
exclusive rights to control the reproduction (including modification, translation, 
digitalisation, etc.) and the communication of the record. One must however bear in mind 
the particularities of the information embodied in the “work”, and of the special 
relationship that exists between the “author” and the patient. Those important specificities 
have a dramatic influence before and after the creation of the “work” and its protection 
through copyright. 
 
The work is created with data relating to the patient, his body, his health and the treatment 
he undergoes. This data is subject to very strict sensitive data protection and privacy rules. 
Furthermore, it is collected in a practitioner – patient relationship, which is governed by 
professional ethics and secrecy rules. Even before creating the work, the practitioner is 
bound by those rules and must respect the special nature of the data. Accordingly, the 
processing of the data may only occur with the agreement of the patient, and conforming to 
the law, the purposes of the processing and the proportionality principles. Actually, at this 
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level, the creation of a copyrighted work with the data may be analysed as being part of the 
processing of the data, namely the creation of a record with the data. Therefore the creation 
of the work is only possible thanks to the will of the patient to choose this practitioner and 
to communicate to this latter his personal data. As a preliminary question, one could 
wonder if this agreement of the patient to record his personal data extends to the matter of 
creating a copyrighted work with them included, and if claiming copyrights on such a file 
would be a loyal behaviour towards the patient. At the very least, one could argue that, in 
such situation, the agreement of the patient is given completely in the framework of a trust 
relationship and on the implicit condition that the practitioner respects his patient’s rights. 
 
The fact of creating a copyrighted work will never modify or alter the nature of the data, 
and the same privacy, secrecy and data protection rules will apply to the copyrighted work. 
This will directly affect the normally “exclusive” character of copyrights: the practitioner 
will not be the sole person to decide when, how and whom the record will be reproduced 
for or communicated to. Those acts will not be allowed without the prior consent of the 
patient, and in general, all the rights a patient could claim with respect to a “traditional” 
record should also be recognised to him as regards the copyrighted work. The author should 
therefore never communicate or reproduce the work, or authorise such acts without the 
authorisation of his patient, unless he does it in a way that does not infringe his professional 
ethic, his secrecy obligations and the laws on data protection. In practice, it means that he 
will almost always need the authorisation of his patient. 
 
Could he however invoke his copyrights towards colleagues, medical institutions or even 
his client himself? In other words, knowing that the author could have some copyrights on 
his record, should the client ask the permission of its author in order to reproduce or 
communicate the work to somebody? 
 
First of all, one must stress that in general, the patient’s minimal rights encompass a right to 
access his record and to get a copy of it. Where some costs may be charged to the client for 
exercising his right to get a copy, these costs would only cover the administrative and/or 
material disbursements and in no way any “royalty”. Whereas the right to access a work is 
not as such recognised as being part of the exclusive rights of the author (this is actually a 
debated issue at the moment), the right to receive a copy of the record derogates from the 
author’s exclusive “copy”-right to reproduce the work. One could indeed not imagine 
another situation where somebody could have the right to ask an author the delivery of a 
free copy of his work. 
 
Once in possession of a copy of his record, according to copyright rules and related 
exceptions, the patient could only make private copies and communicate the work privately 
(usually, only within the family circle). Accordingly, from a strict copyright prospective, 
the patient could not communicate his record to anybody outside his close family without 
the author’s consent. In such scheme, one could imagine a practitioner or a health 
institution could not allow his patient to communicate his record’s copy to a competitor in 
order to restrain their clients from going elsewhere, or could sell the transfer of the record. 
This idea is quite appalling and such deviant use of copyright could instinctively be deemed 
abusive and unethical.  
 
This practice would be contrary to some fundamental rights of the patient.  In relation to the 
patient’s right to access his record, one has frequently put forward the idea of the patient’s 
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property right to this record2. During a period of time, the French public health code 
provided explicitly that the patient was the owner of his record. This concept has been 
debated. Some authors are intent to make a link between the ownership of the record and 
the ownership of one’s own body, which is an idea that is, as such, strongly criticised. 
Some other authors describe the access right as a kind of right in rem or an intellectual 
property of the patient on the data relating to him. Whereas it is difficult to accept the 
existence of a right in rem relating to immaterial and abstract subject matter such as 
information, we do not back up the idea of an intellectual property on patient’s data, as all 
intellectual property rights are provided for in order to protect the results of the human 
intellect’s work, namely the “intellectual works”. Therefore, one may not easily accept to 
grant somebody an intellectual property on pure data relating to the nature and the actual 
condition of his own body. Finally, some authors compared the access right to an 
outstanding information right, which is inseparable and necessary to the exercise of another 
patient right, namely the right of free determination. This right confirms the autonomy of 
the patient in the caring for his health, and its corollaries are the free choice of professional 
practitioner and the liberty to change the latter. 
 
In summary, as well as the author not being able to oppose the patients’ right to attain a 
copy of his record, the author cannot oppose the communication of this record to a 
competitor, nor the modification and reuse of this record by this competitor in the 
framework of the continuance of the patient’s cares, for this would breach the patient’s 
fundamental right to self-determination. 
 
Finally, in the rare cases where a practitioner could claim copyrights on certain elements of 
his patient’s record, one could wonder in which circumstances and towards whom this 
practitioner could actually enforce these copyrights. At first sight, one could put forward 
that the copyrights of the practitioner could be enforced in cases whereby some use of the 
record is done by the patient or with his consent, and when this use is not protected or 
covered by one of his patient’s rights. One could for example think of the case when, for a 
reason or another, the patient would decide to publish his medical record. One could also 
think of cases when only some copyrighted materials, that would not encompass any 
medical data, were extracted from the record (a copyrighted lay out for example) and 
reused in some ways that are covered by the exclusive rights of the author. 
 
Should we have to summarise the analysis that is outlined here above, we could draw a 
general principle according to which, even if in some special and rare cases, practitioners 
could possibly be granted copyrights on the records they created, those copyrights should 
never be used in order to distort the patient’s rights.  
 
 
PART II. Intellectual Property on biobanks? 
 
Biobanks are known as the compilations of human biological material (organs, tissue, cells, 
blood, DNA, etc.) where each sample usually contains very personal information of the 
donator3. These samples might have been collected through diagnosis and treatment 
procedures, or else, on the sole purpose of creating a biobank.   
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These compilations represent, for their creators, great investments, in terms of effort, 
funding, human resources and time. This is the reason why the creators of biobanks seek 
the protection of their work, especially through the intellectual property right regime.   
 





A database is a collection of independent elements, including artistic, literary, musical 
works, texts, data or other materials arranged in a systematic way and individually 
accessible by electronic or other means4. It may contain a wide range of material items 
(such as rocks, stamps, human tissues, etc.) or immaterial items (such as any kind of 
information, contact details, medical data, etc.). One must bear in mind that those items 
may be protected by copyright (songs, photographs, etc.), by other intellectual property 
rights (patents, trademarks, etc.) or by other types of legal protection (privacy as regards 
medical data for example). On the contrary, they also might not benefit from any protection 
at all (such as weather data, astrological data, rocks, etc.).  
 
Biobanks are to be considered as databases. The fact that they contain biological material 
doesn’t lead to their exclusion from the database regime.  
 
Databases consist of a structure and some content. The structure is the frame, the 
“container”, where elements are arranged following some criteria of selection chosen by the 
creator. The indexation and the search systems, as well as the whole layout of the database 
and its interfaces, are also part of this structure. The content represents the sum of all the 
elements, which are gathered and individually accessible in the database.  
 
This distinction between the structure and the content is very important for the analysis of 
the protection provided for by intellectual property rights. Databases may be protected by 
traditional copyright and/or by another specific database right often referred to as “sui 
generis” right. Copyright and sui generis rights protect databases differently according to 
their objects and criteria of protection.  
 
Copyright protects the structure, as long as it is original. In other terms, copyright will 
extend to the criteria of selection, the indexation and search systems, the layout and the 
interfaces as long as they are marked by the creator’s personality or prove to be the result of 
the creator’s “skill, judgement and labour”. In order to appraise the originality of the 
structure, one will also take into account, colours, forms and schemas employed in the 
disposition and presentation of the elements within the database. This reasoning is exactly 
the same as regards biobanks. Indeed, the way the different biological materials are sorted, 
classified, linked together and accessible, on the basis of indexation menus, descriptions, 
entries, etc. may be copyrighted.   
 
Depending on the terms of the contracts pertaining to the creation of the structure of the 
biobank, and their role in that creation either the practitioner, the hospital, any other 
contractor or any combination of them could be the copyright owner(s). Copyright entitles 
its owner(s) to prevent any other person from reproducing and communicating the 
database’s structure to the public. However, some third parties will benefit from certain 
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exceptions in specific circumstances involving public security, teaching and scientific 
researches purposes, private purposes, or other legitimate interests.   
 
Databases may also be protected by sui generis rights. Sui generis rights protect the 
substantial investment of the database’s maker from a qualitative and quantitative 
perspective in either the obtaining, verification or presentation of the content. The obtaining 
refers to the collection of data or items. The verification pertains to the checking of the 
accuracy of the data or the items when the database is created and during its operation. The 
presentation relates to the processing of the data, as well as to their organisation, in order to 
ensure their individual access and their methodical arrangement. The term “investment” 
refers not only to money but also to time, effort and human resources invested in those 
activities.  
 
The sui generis rights owner is the person who has made the investment. In the case of 
biobanks, it might frequently be the hospital or research institution. By virtue of this right, 
this entity is enabled to prohibit the substantial extraction and reuse of the database by any 
third party. On the contrary, non-substantial extractions and reuses may be undertaken by 
third parties, without the right owner’s authorisation, as long as these acts aren’t made in a 
repeated and systematic way that would imply a conflict with the normal exploitation of the 
database or produce an unreasonable prejudice to the legitimate interests of the database’s 
maker5. The substantiality is assessed from a quantitative and a qualitative points of view. 
These criteria are highly variable from one case to another, what implies that judges will 
play an important role in their application and interpretation. 
 
Accordingly, sui generis rights might protect biobanks. This protection is weaker than 
copyright because only biobanks demanding a substantial investment in the obtaining, the 
verification or the presentation of their content may be protected and anyway, the non-
substantial extraction and reuse can be carried out by anybody without the right holder’s 
permission.  
 
Moreover, a theory restraining the application of the sui generis rights protection, and more 
precisely narrowing the substantial investment condition, has appeared in the late 90’s in 
The Netherlands and is increasingly spreading its influence throughout Europe. According 
to this so-called spin-off theory, the by-products resulting from activities whose main 
objective aren’t the obtaining, verification and/or presentation of the content of the database 
cannot enjoy sui generis rights. The spin-off theory is grounded on the necessity of a link 
between the substantial investment in any of those activities and the aim of creating a 
database. In other words, any investment made in order to pursue another aim than creating 
a database should be put aside when assessing the fulfilment of the investment condition to 
obtain a sui generis right. This theory has already been examined by the European Court of 
Justice which has clearly stated that the fixture lists containing dates, time, etc. of matches 
of the British football league are considered as databases, but cannot be protected by sui 
generis rights because of the lack of substantial investment. Indeed, the normal activity of 
the British football leagues, which is basically to organise the dates and times of home and 
away teams playing in the matches, is so integral to the creation of the database’s content, 
that it cannot claim any sui generis rights on it6. A similar situation could occur in the 
medical sector. One can imagine two extreme hypothesis: a) The hospital’s staff stores in a 
biobank, for hypothetical further research purposes, samples resulting from everyday-
treatments applied to patients (in this case, we will suppose that no other work is done than 
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the mere storing of samples that were used in order to treat the patients); and b) The 
hospital’s staff collects samples from patients exclusively in order to create a biobank. If we 
apply the spin-off theory, the first biobank wouldn’t be protected by sui generis rights, 
while the second one would be. In the first case, the hospital hasn’t invested in the 
obtaining, verification or presentation of the samples gathered in the biobank. It has paid its 
staff, spent time and invested in medical devices in order to care for the patient’s health. 
Subsequently, it has reused the patient’s samples in the framework of a biobank with 
research purposes, without doing any other extra substantial investment. Therefore, there 
are no sui generis rights. This means that, from a strict sui generis right point of view, and 
leaving aside any other concern pertaining to the biobank or its content (such as privacy 
protection, confidentiality clauses, secrecy rules, access rights, technical means, contractual 
provisions, etc.), any third party could extract and reuse substantial parts of the biobank’s 
content without the hospital’s permission. In the second case, the hospital has expended its 
funding, resources, effort and time in the three activities above-mentioned, which lead to 
the creation of a database. For this reason, the hospital would hold sui generis rights. It 
seems logical to proceed this way, especially when we look at the function of the sui 
generis rights, which is the protection of the database maker’s substantial investment. If 
there is no substantial investment, there are no sui generis rights on the database to claim 
against third parties.    
 
We have already mentioned that each item that is inserted in a database might also be 
legally protected. In the case of biobanks, can biological materials enjoy any protection? 
First of all, biological materials consist of samples of tissue, DNA, blood, cells, etc. which 
have been extracted from patients. In order to take those samples from the patients, the 
practitioner must have asked the patients’ consent and explained them the purpose of the 
analysis or treatment. Once these samples have been obtained, the practitioner or the 
hospital may decide to gather them in a biobank for research purposes. However, once 
again, this may only be done with the preliminary and informed consent of the concerned 
patient. The ulterior commercialisation of this biobank would also be subject to the 
patients’ consent. In other words, one must stress that the items that are gathered in the 
biobank are first of all protected by data protection and secrecy rules. Could intellectual 
property rights protect these items? One could not seriously imagine claiming any 
copyright on human biological materials, unless one could first pretend that these materials 
may be considered as literary and artistic works, which seems at first sight to be difficult as 
well as inept. Given the recent developments as regards the patentability of biotechnology, 
patent rights may also be considered. Indeed, for example, the isolation of the samples in 
order to be identified, purified, classified and reproduced outside the human body may lead 
to an invention susceptible of being protected by patent7. Therefore, depending on the 
interventions and treatments applied to the samples, those database items could be patented 
or patentable.             
 
II.2 Protection by industrial property rights: patents 
 
The use of biobanks, and specially, the researches carried out on the basis of their content 
might result in an invention, which is, according to the traditional definition, a technical 
solution found to solve a technical problem. An invention may be the subject of a patent if 
the conditions of protection are met and if formalities (the filing of applications) are 
executed by the inventor.   
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In order to be patentable, an invention must fulfil three conditions, namely novelty, 
inventive step and industrial application.  
 
An invention is new if it is not part of the state of the art, which comprises everything made 
available to the public by any mean, before the filing date of the patent application. An 
invention is inventive if having regard to the state of the art, it is not obvious to a person 
skilled in the art. The criterion of industrial application refers to the adequacy of the 
invention to be used in any industrial sector, comprising the agricultural field.  
The patent holder can prevent third parties from using, manufacturing, selling, exporting,  
importing and exploiting its invention, without its authorisation8. This right lasts 20 years 
after the filling of the patent application.  
 
The inventions resulting from researches and developments made on the basis of a biobank 
could probably be biotechnological inventions. At European level, the protection of these 
inventions formed the subject of important controversies that resulted in the adoption of 
directive 98/44/EC9. In the framework of this paper relating to intellectual property rights 
on medical data and to the conflicts that may occur between those rights and the patients’ 
rights, we must draw special attention on the debate surrounding the patient’s informed 
consent to the filing of a patent on a biotechnological invention based on his own biological 
material. Indeed, recital 26 of this directive expresses that the patient who has given 
biological material that has served as the basis of an invention or has been used by this 
latter, must give its free and informed consent as regards the filling of the patent application 
on such invention, according to its national law. Unfortunately, the fact that this provision 
has been inserted in the recitals and not in the articles of the directive jointly with the fact 
that, in some European countries, the national state authorities have found this provision 
controversial and too advanced, have more or less emptied this principle at the directive’s 
implementation level. However, even if the patient’s consent is not a condition to 
patentability according to some member states’ patent law, the privacy and secrecy laws 
still apply, and one could wonder whether solely on those grounds, the consent of the 
patient to such use of part of his body does not remain mandatory. This sometimes called 
“misplaced” ethical rule, present in the recitals of the directive, remains therefore a 
reference that must be taken into account when tackling the issue of filing patents on 
biotechnological inventions.      
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